Back to top
more

Ardelyx (ARDX)

(Delayed Data from NSDQ)

$6.22 USD

6.22
2,265,073

+0.26 (4.36%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $6.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Ardelyx (ARDX) Stock?

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Implied Volatility Surging for Ardelyx (ARDX) Stock Options

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Is a Surprise Coming for Ardelyx (ARDX) This Earnings Season?

Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Editas (EDIT) to Report Q3 Earnings: What's in the Cards?

On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

Is the Options Market Predicting a Spike in Ardelyx (ARDX) Stock?

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -25.00% and 19.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -6.25% and 498.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ardelyx (ARDX) Q1 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Ardelyx (ARDX) Stock Options

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Ardelyx (ARDX) Stock Jumps 6.8%: Will It Continue to Soar?

Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -23.08% and -3.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Ardelyx (ARDX) Report Negative Q3 Earnings? What You Should Know

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?

Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Ardelyx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Ardelyx

Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why Momentum Investors Will Love Ardelyx (ARDX)

Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Amends Linzess Agreement with AstraZeneca in China

Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.